nad+ protocol: Frequently asked questions

Yes. Metabolic syndrome elevates CD38 expression, the enzyme that degrades NAD+ in response to chronic inflammation. Men with metabolic syndrome burn through NAD+ faster than healthy controls, which means standard dosing may not produce the same elevation. Prioritise NMN over NR if you have insulin resistance or elevated fasting glucose. Hepatic NAD+ restoration improves glucose metabolism through SIRT1-mediated suppression of gluconeogenesis. Add quercetin at 1000mg daily to reduce inflammation-driven CD38 activity. Monitor fasting glucose and HbA1c at 12 weeks. Improvements in these markers confirm that the NAD+ protocol is addressing metabolic dysfunction, not just raising blood NAD+ levels.

No. Standard multivitamins contain niacin (vitamin B3) or nicotinamide, which are NAD+ precursors but follow a different metabolic pathway. Nicotinamide converts to NAD+ through the salvage pathway, which is rate-limited by the enzyme NAMPT. During high metabolic demand (endurance training), NAMPT becomes saturated. Meaning additional nicotinamide doesn't meaningfully raise NAD+ levels. NR and NMN bypass this bottleneck by entering cells directly and converting to NAD+ through enzymes that aren't rate-limiting. A 100mg niacin dose in a multivitamin provides baseline vitamin sufficiency but won't address exercise-induced NAD+ depletion the way 500mg NMN does.

Missing occasional doses won't negate benefits, but inconsistent dosing prevents NAD+ levels from stabilising. NAD+ has a relatively short half-life in tissue (hours, not days), meaning daily supplementation is necessary to maintain elevated levels. If you miss 2–3 days, tissue NAD+ drops back toward baseline. You're not losing prior adaptations, but you're not maintaining the elevated state either. For athletes mid-training block, prioritise post-training doses over pre-training doses if choosing one. Replenishment matters more than acute loading when training frequency is high.

NAD+ protocols don't produce acute ergogenic effects like caffeine or beta-alanine. The benefit is cumulative and becomes apparent across training blocks. Sustained power at threshold, faster recovery between hard sessions, and maintained training quality late in multi-week build phases. If you're testing it during a single workout, you won't feel a difference. Most athletes notice measurable changes (subjective and objective) after 3–4 weeks of consistent dosing when NAD+ levels stabilise and mitochondrial adaptations compound. Track metrics like average power during threshold intervals or perceived recovery quality between sessions. Those are where NAD+ sufficiency shows up, not in maximum sprint power or single-effort tests.

NAD+ restoration takes 4–8 weeks to produce subjective improvements in energy and recovery because the downstream effects. Mitochondrial biogenesis, sirtuin-mediated metabolic shifts, and senescent cell clearance. Lag behind circulating NAD+ elevation. Blood NAD+ levels rise within 7–14 days at therapeutic doses, but tissue-level changes require sustained elevation. If you're dosing at 250mg daily or lower, you may not be exceeding the threshold for sirtuin activation. Increase to 500mg minimum and add resveratrol to amplify NAD+-dependent deacetylation. Subjective effects typically appear between weeks 4 and 6 in men over 55 with baseline NAD+ depletion.

No. Standard multivitamins contain nicotinamide (niacinamide) at 20–50mg, which enters NAD+ synthesis through the salvage pathway via NAMPT. The same enzyme that declines 30–50% after age 50. The dose is too low and the pathway is rate-limited in aging populations. Nicotinamide riboside and nicotinamide mononucleotide bypass NAMPT entirely, which is why therapeutic doses (500–1000mg) produce measurable NAD+ elevation while multivitamin niacin does not. If you're over 55 and experiencing fatigue or reduced recovery, dietary niacin intake is insufficient to restore NAD+ to functional levels.

Consider increasing to 750mg daily split into two doses (morning and pre-training) after eight weeks at 500mg if recovery rate hasn't improved. Older athletes show steeper age-related NAD+ decline and may require higher precursor intake to achieve the same tissue-level NAD+ elevation as younger cyclists. A 2022 study published in Aging Cell demonstrated that adults over age 55 needed 750–1000mg NMN daily to match the NAD+ bioavailability achieved with 500mg in adults under 40. Watch for mild gastrointestinal upset (nausea, loose stools) as the primary dose-limiting side effect. If it occurs, split the dose into smaller increments taken 4–6 hours apart rather than reducing total intake.

Verify three things before concluding non-response. First, confirm morning dosing timing. Afternoon or evening administration misses the NAMPT enzyme peak and reduces conversion efficiency significantly. Second, assess methylation cofactor adequacy by testing plasma homocysteine (should remain below 10 μmol/L). Elevated homocysteine indicates methylation bottleneck is limiting NAD+ restoration. Third, evaluate baseline mitochondrial function through lactate threshold testing or VO2max assessment. Severe mitochondrial dysfunction may require additional interventions (CoQ10, PQQ, Energy Mitochondria Fatigue Bundle) before NAD+ restoration produces subjective benefit.

Switch from nicotinamide riboside to nicotinamide mononucleotide or reduce the dose by 50% for two weeks. Flushing results from excess nicotinamide conversion to nicotinic acid (niacin), which triggers histamine release and vasodilation. NMN bypasses one enzymatic step that generates this byproduct, reducing flushing incidence. If symptoms persist on NMN at reduced dose, the methylation support stack may be insufficient. Increase TMG to 2g daily to accelerate nicotinamide clearance through the methylation pathway.

Discard it immediately. Texture changes indicate moisture exposure and likely degradation. Nicotinamide mononucleotide is hygroscopic, meaning it absorbs moisture from air, which accelerates breakdown into nicotinamide and ribose. Neither of which effectively raises NAD+ levels when separated. Properly stored NMN remains a fine, free-flowing powder. If you're storing NMN in the refrigerator, use a desiccant packet inside an airtight container to prevent condensation during temperature fluctuations when you remove it for dosing. This is one of the most common preparation mistakes we see. Athletes assume refrigeration alone is sufficient, but repeated opening in humid environments causes degradation within 2–3 weeks.

No dosing adjustment required, but understand the mechanistic interaction. Metformin activates AMPK (AMP-activated protein kinase), which increases cellular energy demand and accelerates NAD+ consumption through PARP and sirtuin pathways. This means metformin users may benefit from the higher end of the NAD+ precursor dosing range (500mg vs 250mg) to compensate for increased NAD+ turnover. The longevity researchers nad+ protocol at institutions where metformin is commonly used defaults to 500mg NR daily when metformin exceeds 1000mg daily dose.

Increase your weekly Zone 2 volume to at least 6–8 hours before concluding the protocol isn't working. NAD+ precursors amplify the mitochondrial adaptations stimulated by aerobic base training. If you're primarily doing high-intensity intervals without sufficient Zone 2 foundation, you're not creating the metabolic signal that NAD+ supplementation enhances. Research from the Norwegian University of Science and Technology found that cyclists with fewer than 5 hours of weekly Zone 2 training showed minimal response to NR supplementation, while those training 8+ hours weekly at 60–70% max heart rate demonstrated 12–18% improvements in lactate threshold power. The precursor itself doesn't create mitochondria. It supports the biogenesis process triggered by sustained aerobic demand.

Check three variables: dose size, timing consistency, and baseline NAD+ status. If you're dosing 250mg or less, you're likely below the enzymatic threshold. Increase to 500mg twice daily. If you're dosing inconsistently or with meals, NAMPT isn't active when the substrate arrives. Shift to strict fasted timing. If both are correct, you may have sufficient baseline NAD+ (younger individuals or those with excellent metabolic health) and won't notice subjective changes. Objective markers like VO2max or fasting glucose are more reliable than subjective energy in this case.

Dose during a fed state. Insulin elevation suppresses AMPK and SIRT1, which downregulates NAMPT transcription. The precursor enters circulation but most of it gets shunted into methylation pathways or excreted rather than converted to NAD+. Studies show fasted-state NMN produces 3–4× higher hepatic NAD+ elevation than fed-state dosing at identical doses. If fasting isn't possible, dose at least four hours post-meal when insulin has returned to baseline. That restores partial NAMPT activity.

Metformin and berberine both activate AMPK, which upregulates NAMPT transcription. This is synergistic with NAD+ precursors. Our experience shows users on metformin 500–1000mg daily report faster onset of NAD+ effects (3–4 days vs 5–7 days) because AMPK is already priming the salvage pathway. The biohackers nad+ protocol stacks well with AMPK activators; no dose adjustment needed. Avoid combining with niacin (flush-form vitamin B3) if you're on metformin. Both compete for the same methylation enzymes and can cause lactic acidosis in rare cases.

Check substrate availability first. MOTS-c increases NAMPT expression, but if nicotinamide substrate is depleted (common in diets low in B3 or tryptophan), enzyme upregulation won't translate to NAD+ synthesis. Serum nicotinamide levels below 5 μmol/L indicate substrate limitation. Supplementing with 500mg NMN or niacin restores the precursor pool within 7–10 days. Second, verify injection technique if using subcutaneous administration: improper depth or alcohol contamination during reconstitution can denature peptides before absorption. Third, consider genetic polymorphisms in NAMPT or NMNAT genes. Approximately 8–12% of individuals carry variants that reduce enzyme activity regardless of transcriptional upregulation.

Combine them. The mechanisms are complementary. MOTS-c activates AMPK and upregulates NAD+ synthesis, while fasting depletes cellular ATP and glucose, creating the energetic stress that amplifies AMPK signaling. Research in rodent models showed fasting for 16–18 hours before MOTS-c administration increased skeletal muscle NAD+ by an additional 23% compared to fed-state administration. The practical protocol: administer MOTS-c in a fasted state (12+ hours), wait 30–60 minutes, then consume NAD+ precursors with the first meal to capitalize on both the fasting-induced AMPK activation and MOTS-c's enzymatic upregulation.

Preliminary evidence supports this application but human data is minimal. MOTS-c crosses the blood-brain barrier in rodent models, with CSF concentrations reaching 40–50% of serum levels within 90 minutes of administration. A 2023 study in aged mice showed MOTS-c increased hippocampal NAD+ by 28% and improved spatial memory performance in Morris water maze testing. Nasal spray delivery may enhance CNS bioavailability by bypassing first-pass metabolism. Intranasal MOTS-c formulations like those used in research show direct olfactory nerve transport to brain tissue. For cognitive applications, dosing of 2.5–5mg nasal spray daily paired with 500mg NMN appears in ongoing neuroprotection research protocols, though Phase II human data won't be available until late 2026.